Clinical Research Directory
Browse clinical research sites, groups, and studies.
Transcriptional and Epimetabolic Profile of Breast Carcinoma With Luminal or HER2+ or Locally Advanced Triple-negative Histotype in Patients With/Without Previous Clinical History of Metabolic Syndrome
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Summary
This prospective pilot study of biological specimens aims to identify new prognostic and predictive biomarkers of response to standard therapy for local advanced BC, as well as to identify new targets for the development of immuno- therapeutic protocols. First aim is therefore to expand our knowledge to increase the response to preoperative treatment, intensify treatment patterns, and select patients based on clinical parameters. In this regard, it appears imperative to investigate yet under-investigated factors that might impair the response to standard therapy for local advanced BC including association to metabolic syndrome and analysis of tumoral and stromal features supporting a tumor microenvironment impenetrable to both drugs and immune system cells.
Key Details
Gender
FEMALE
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
120
Start Date
2024-02-01
Completion Date
2026-07-01
Last Updated
2024-02-15
Healthy Volunteers
No
Conditions
Interventions
Influence of metabolic syndrome on the achievement of pathological complete response
The proposed activity aims to assess the transcriptional and epimetabolic profile of locally advanced luminal or HER2+ or triple negative breast cancer in patients with/without metabolic syndrome to predict the therapeutic response to neoadjuvant chemotherapy.
Locations (1)
Fondazione Policlinico Universitario A. Gemelli - IRCCS
Roma, Italy